Stock Analysis
Enovis Corporation (ENOV) Stock Analysis
Enovis Corporation (ENOV) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Enovis Corporation (ENOV) currently has an AIQ Score of 47/100, indicating a neutral setup. Value is the strongest factor at 74/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ENOV at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $19.28 |
| AIQ Score | 47/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.18B |
| P/E Ratio | 5.88 |
| Forward P/E | — |
| EPS | -$0.02 |
| Revenue TTM | $582.78M |
| Dividend Yield | 0.00% |
| Beta | 1.45 |
| Volume | 3.18M |
| 52-week range | $18.08-$33.85 |
| RSI 14 | 22.3 |
| 50-Day SMA | $25.31 |
| 200-Day SMA | $24.56 |
| Analyst Price Target | $35.75 |
| Next Earnings | Nov 5, 2026 |
ENOV
OverviewENOV Stock Analysis Summary
Enovis Corporation (ENOV) currently has an AIQ Score of 47/100, indicating a neutral setup. Value is the strongest factor at 74/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ENOV has AIQ Score of 47/100 with Value base of 74/100 and fading Momentum at 24/100. Wait for component alignment before adding exposure.
Value (74/100) leads while Momentum (24/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 4.73% stock move · ENOV classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ENOV Bullish or Bearish Right Now?
ENOV currently has a neutral overall setup. Value is the strongest factor at 74/100, while Momentum is weakest at 24/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +85.43% upside from the latest quote.
- - Momentum is weak at 24/100.
- - Risk Resilience is weak at 40/100.
- - Price is -21.50% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (35 vs 7).
Current Consensus
ENOV's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 3 neutral, and 35 sell votes. ENOV's 14-day RSI is 22.3, which places the stock in an oversold momentum range. ENOV's beta is 1.45, indicating greater market sensitivity than the broad market.
What Changed in ENOV?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the ENOV Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ENOV Decision Framework
Public evidence layers, setup checks, and risk context for Enovis Corporation.
Enovis Corporation (ENOV) Stock Analysis
Enovis Corporation has an AIQ Score of 47/100 in a Neutral regime. Value is strongest at 74/100. Beta is 1.45, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ENOV is in a Neutral AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that value leads at 74/100 while momentum lags at 24/100. |
| Factor Evidence | Momentum 24/100 · Value 74/100 · Quality 42/100 · Risk 40/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 74/100.
Momentum is 24/100 and RSI (14) is 22.3.
ENOV is in a Neutral regime at 47/100.
Risk factor is 40/100 with beta 1.45 and annual volatility 63.37%.
Current conflict: value leads at 74/100 while momentum lags at 24/100.
ENOV Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ENOV Fundamentals
ENOV valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ENOV Technical Analysis
ENOV technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ENOV Stock Catalysts
Track ENOV earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ENOV Dividend Analysis
ENOV dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ENOV Financial Data
ENOV revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ENOV Risk Analysis
ENOV volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ENOV Stock News
ENOV stock news, market tone, recent headlines, and catalyst context.
ENOV vs Medical Devices Peers
Current peer cohort: ENOV · EW · GEHC · GMED · HAYW. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ENOV Current stock | 47/100 | 74/100 | 24/100 | 40/100 | -0.47 | 63.37% | Current |
| EW Edwards Lifesciences | 46/100 | 28/100 | 23/100 | 77/100 | 0.27 | 25.38% | ENOV vs EW |
| GEHC GE HealthCare | 49/100 | 65/100 | 21/100 | 60/100 | -0.43 | 35.02% | ENOV vs GEHC |
| GMED Globus Medical | 54/100 | 55/100 | 21/100 | 75/100 | 0.63 | 48.96% | ENOV vs GMED |
| HAYW Hayward Holdings | 55/100 | 64/100 | 25/100 | 74/100 | -0.5 | 33.10% | ENOV vs HAYW |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jul 3, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ENOV
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ENOV
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ENOV Stock FAQ
What is ENOV stock price today?
Enovis Corporation's current stock price is $19.28. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ENOV bullish or bearish right now?
ENOV's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ENOV's market cap?
ENOV's market cap is $1.18B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ENOV's current P/E ratio?
ENOV's current P/E ratio is 5.88 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ENOV's RSI?
ENOV's 14-day RSI is 22.3 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ENOV above its 50-day and 200-day moving averages?
ENOV is -23.84% from its 50-day SMA and -21.50% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ENOV's next earnings date?
ENOV's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ENOV pay a dividend?
ENOV's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.